Literature DB >> 20842669

Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma.

Yun Cao1, Xiao-Ping Miao, Ma-Yan Huang, Ling Deng, Dong-Xin Lin, Yi-Xin Zeng, Jian-Yong Shao.   

Abstract

The FAS receptor/ligand system is a key regulator of apoptotic cell death and corruption of this signaling pathway has been shown to participate in carcinogenesis. Functional polymorphisms in the FAS (FAS -1377G/A) and FASL (FASL -844T/C) genes alter their transcriptional activity. Therefore, we examined the association between these polymorphisms and the risk of developing nasopharyngeal carcinoma (NPC). FAS -1377G/A and FASL -844T/C genotypes were determined by PCR-based RFLP analysis in 582 patients with NPC and 613 frequency-matched controls. We observed a significantly increased risk of NPC associated with the FAS -1377AA genotype [odds ratio (OR) = 1.69, 95% confidence interval (CI) = 1.21-2.35] compared with the FAS -1377 GG genotype. In addition, elevated NPC risk was also found among subjects carrying both FAS -1377AA and FASL -844CC genotypes compared with both FAS -1377GG and FASL -844CT or -844TT, the OR was 2.39 (95% CI = 1.50-3.79). After stratification by smoking status, heavy smokers (≥15 pack-years) carrying FAS -1377AA genotype had an increased risk of NPC compared with FAS -1377GG genotype (OR = 3.48, 95% CI = 1.66-7.30). Furthermore, we observed a statistically significant interaction between the two polymorphisms and heavy smoking status (OR = 5.92, 95% CI = 1.91-18.3). Our study provides the first evidence that functional FAS -1377 G/A and FASL -844 T/C polymorphisms are associated with the risk of NPC, and this association is especially noteworthy in tobacco smokers.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842669     DOI: 10.1002/mc.20676

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  14 in total

Review 1.  Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factors.

Authors:  Allan Hildesheim; Cheng-Ping Wang
Journal:  Semin Cancer Biol       Date:  2012-01-25       Impact factor: 15.707

2.  FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis.

Authors:  Ou Huang; Min Jiang; Xi Zhang; Xiaosong Chen; Jiayi Wu; Kunwei Shen
Journal:  Tumour Biol       Date:  2014-01-11

3.  Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.

Authors:  Sarika Daripally; Sateesh Reddy Nallapalle; Saritha Katta; Vidudala V T S Prasad
Journal:  Tumour Biol       Date:  2015-05-06

4.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

5.  Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis.

Authors:  Behnaz Valibeigi; Zahra Amirghofran; Hossein Golmoghaddam; Reza Hajihosseini; Fatemeh M Kamazani
Journal:  Pathol Oncol Res       Date:  2013-11-12       Impact factor: 3.201

6.  Increased resistance to Staphylococcus aureus endophthalmitis in BALB/c mice: Fas ligand is required for resolution of inflammation but not for bacterial clearance.

Authors:  Norito Sugi; Emily A Whiston; Bruce R Ksander; Meredith S Gregory
Journal:  Infect Immun       Date:  2013-04-08       Impact factor: 3.441

7.  Association between FAS-1377 G/A polymorphism and susceptibility to gastric cancer: evidence from a meta-analysis.

Authors:  Zhiming Wu; Huangen Wang; Xiufeng Chu; Jiang Chen; Shengyang Fang
Journal:  Tumour Biol       Date:  2013-05-01

8.  FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects.

Authors:  Lei Xu; Xin Zhou; Feng Jiang; Man-Tang Qiu; Zhi Zhang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

Review 9.  FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls.

Authors:  Zhou Zhong-Xing; Mi Yuan-Yuan; Ma Hai Zhen; Zou Jian-Gang; Zhang Li-Feng
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

Review 10.  Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies.

Authors:  Yeqiong Xu; Bangshun He; Rui Li; Yuqin Pan; Tianyi Gao; Qiwen Deng; Huiling Sun; Guoqi Song; Shukui Wang
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.